person · Reporting owner

ROTHBLATT MARTINE A

Disclosed activity across 2 companies

Tapewire entity: 665
SEC CIK: 0001106578

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BETA Technologies, Inc.BETA · Entity 1930	Director	June 11, 2026	June 12, 2026
UNITED THERAPEUTICS CorpUTHR · Entity 664	Director · Chairperson & CEO	October 13, 2026	October 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BETA Technologies, Inc.

Report date June 11, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A common stockSEC Table I · non-derivative	Direct	8,213	Reported balance After 2026-06-11 transaction · row 1 1 source row Row 1 · 2026-06-11 · Grant · Acquired 7,142 · Balance 8,213

UNITED THERAPEUTICS Corp

Report date October 13, 2026 · Filed October 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Indirectby Trust	333,943	Reported balance After 2026-10-13 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2026-10-13 · Exercise / conversion · Acquired 9,500 · Balance 333,943 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	333,304	Reported balance After 2026-10-13 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2026-10-13 · Sale · Disposed 639 · Balance 333,304 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	330,964	Reported balance After 2026-10-13 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2026-10-13 · Sale · Disposed 2,340 · Balance 330,964 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	329,472	Reported balance After 2026-10-13 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2026-10-13 · Sale · Disposed 1,492 · Balance 329,472 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	327,965	Reported balance After 2026-10-13 transaction · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · 2026-10-13 · Sale · Disposed 1,507 · Balance 327,965 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	326,513	Reported balance After 2026-10-13 transaction · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · 2026-10-13 · Sale · Disposed 1,452 · Balance 326,513 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	325,883	Reported balance After 2026-10-13 transaction · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · 2026-10-13 · Sale · Disposed 630 · Balance 325,883 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	325,185	Reported balance After 2026-10-13 transaction · row 8 Holding and transaction disclosures are not merged. 1 source row Row 8 · 2026-10-13 · Sale · Disposed 698 · Balance 325,185 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	324,683	Reported balance After 2026-10-13 transaction · row 9 Holding and transaction disclosures are not merged. 1 source row Row 9 · 2026-10-13 · Sale · Disposed 502 · Balance 324,683 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	324,523	Reported balance After 2026-10-13 transaction · row 10 Holding and transaction disclosures are not merged. 1 source row Row 10 · 2026-10-13 · Sale · Disposed 160 · Balance 324,523 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	324,443	Reported balance After 2026-10-13 transaction · row 11 Holding and transaction disclosures are not merged. 1 source row Row 11 · 2026-10-13 · Sale · Disposed 80 · Balance 324,443 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	249,108	Reported balance Holding disclosure · report date 2026-10-13 · row 14 Holding and transaction disclosures are not merged. 1 source row Row 14 · Balance 249,108 F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
Common StockSEC Table I · non-derivative	Indirectby Trust	45,596	Reported balance Holding disclosure · report date 2026-10-13 · row 15 Holding and transaction disclosures are not merged. 1 source row Row 15 · Balance 45,596 F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Indirectby Trust	8,902	Reported balance Holding disclosure · report date 2026-10-13 · row 16 Holding and transaction disclosures are not merged. 1 source row Row 16 · Balance 8,902 F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.76 · Expires 2027-03-15	Indirectby Trust	242,910	Reported balance After 2026-10-13 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2026-10-13 · Exercise / conversion · Disposed 9,500 · Balance 242,910 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023. F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
Common StockSEC Table I · non-derivative	Direct	40,513	Reported balance Holding disclosure · report date 2026-10-13 · row 12 Holding and transaction disclosures are not merged. 1 source row Row 12 · Balance 40,513
Common StockSEC Table I · non-derivative	Indirectby Spouse	166	Reported balance Holding disclosure · report date 2026-10-13 · row 13 Holding and transaction disclosures are not merged. 1 source row Row 13 · Balance 166

Filing footnotes · ownership attribution and instrument terms

F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.

F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.

F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.

F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 11, 2020 Filed Jun 12, 2020 21:02 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,765	$116.38	$321,783.51	Disclosure SEC source: 0001127602-20-019506 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,375 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $115.925 to $116.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 11, 2020 Filed Jun 12, 2020 21:02 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	10,000	$63.22	$632,200.00	Disclosure SEC source: 0001127602-20-019506 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 10, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	10,000	$0.00 Strike: $63.22	$0.00	Disclosure SEC source: 0001127602-20-019363 · form4.xml · derivative · entry 17 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,834 Underlying: Common Stock · 10,000 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 10, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	398	$124.96	$49,732.09	Disclosure SEC source: 0001127602-20-019363 · form4.xml · nonDerivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $124.87 to $125.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 10, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	7,393	$124.32	$919,090.37	Disclosure SEC source: 0001127602-20-019363 · form4.xml · nonDerivative · entry 11 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 538 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $123.80 to $1224.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 10, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,209	$126.31	$279,011.94	Disclosure SEC source: 0001127602-20-019363 · form4.xml · nonDerivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,931 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $122.80 to $123.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 10, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	10,000	$63.22	$632,200.00	Disclosure SEC source: 0001127602-20-019363 · form4.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 09, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	10,000	$0.00 Strike: $63.22	$0.00	Disclosure SEC source: 0001127602-20-019363 · form4.xml · derivative · entry 16 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,834 Underlying: Common Stock · 10,000 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 09, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,423	$126.72	$307,050.07	Disclosure SEC source: 0001127602-20-019363 · form4.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $126.44 to $127.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 09, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	3,550	$125.89	$446,920.15	Disclosure SEC source: 0001127602-20-019363 · form4.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,563 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $125.385 to $126.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 09, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	4,027	$124.90	$502,979.55	Disclosure SEC source: 0001127602-20-019363 · form4.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,113 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $124.36 to $125.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 09, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	10,000	$63.22	$632,200.00	Disclosure SEC source: 0001127602-20-019363 · form4.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 08, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	10,000	$0.00 Strike: $63.22	$0.00	Disclosure SEC source: 0001127602-20-019363 · form4.xml · derivative · entry 15 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,834 Underlying: Common Stock · 10,000 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 08, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	376	$125.66	$47,247.90	Disclosure SEC source: 0001127602-20-019363 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $125.57 to $125.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 08, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	7,473	$125.03	$934,368.62	Disclosure SEC source: 0001127602-20-019363 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $124.57 to $125.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 08, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,151	$123.62	$265,908.56	Disclosure SEC source: 0001127602-20-019363 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,989 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $122.98 to $123.975. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 08, 2020 Filed Jun 10, 2020 20:49 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	10,000	$63.22	$632,200.00	Disclosure SEC source: 0001127602-20-019363 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 05, 2020 Filed Jun 5, 2020 22:53 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	10,000	$0.00 Strike: $63.22	$0.00	Disclosure SEC source: 0001127602-20-019049 · form4.xml · derivative · entry 13 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,834 Underlying: Common Stock · 10,000 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 05, 2020 Filed Jun 5, 2020 22:53 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,053	$124.52	$255,644.08	Disclosure SEC source: 0001127602-20-019049 · form4.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $124.255 to $125.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 05, 2020 Filed Jun 5, 2020 22:53 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	5,477	$123.64	$677,159.30	Disclosure SEC source: 0001127602-20-019049 · form4.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,193 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $123.20 to $124.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 05, 2020 Filed Jun 5, 2020 22:53 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,470	$122.70	$303,058.38	Disclosure SEC source: 0001127602-20-019049 · form4.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,670 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $122.15 to $123.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 05, 2020 Filed Jun 5, 2020 22:53 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	10,000	$63.22	$632,200.00	Disclosure SEC source: 0001127602-20-019049 · form4.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 04, 2020 Filed Jun 5, 2020 22:53 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	10,000	$0.00 Strike: $63.22	$0.00	Disclosure SEC source: 0001127602-20-019049 · form4.xml · derivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,834 Underlying: Common Stock · 10,000 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 04, 2020 Filed Jun 5, 2020 22:53 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	852	$125.26	$106,717.26	Disclosure SEC source: 0001127602-20-019049 · form4.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $124.965 to $125.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 04, 2020 Filed Jun 5, 2020 22:53 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,838	$124.51	$353,346.61	Disclosure SEC source: 0001127602-20-019049 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 992 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $123.96 to $124.935. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 04, 2020 Filed Jun 5, 2020 22:53 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	3,529	$123.38	$435,419.67	Disclosure SEC source: 0001127602-20-019049 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,830 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $122.94 to $123.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 04, 2020 Filed Jun 5, 2020 22:53 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,781	$122.26	$340,009.23	Disclosure SEC source: 0001127602-20-019049 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,359 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $121.88 to $122.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 04, 2020 Filed Jun 5, 2020 22:53 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	10,000	$63.22	$632,200.00	Disclosure SEC source: 0001127602-20-019049 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 03, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	10,000	$0.00 Strike: $63.22	$0.00	Disclosure SEC source: 0001127602-20-018755 · form4.xml · derivative · entry 21 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,834 Underlying: Common Stock · 10,000 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 03, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	3,179	$125.62	$399,330.40	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 16 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F14 · price: This transaction was executed in multiple trades at prices ranging from $125.38 to $125.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 03, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,104	$124.66	$262,286.74	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 15 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,319 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F13 · price: This transaction was executed in multiple trades at prices ranging from $124.37 to $125.265. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 03, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	4,350	$123.82	$538,616.13	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 14 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,423 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F12 · price: This transaction was executed in multiple trades at prices ranging from $123.365 to $124.355. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 03, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	367	$122.57	$44,982.20	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 13 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,773 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F11 · price: This transaction was executed in multiple trades at prices ranging from $122.215 to $122.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 03, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	10,000	$63.22	$632,200.00	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 12 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 02, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	10,000	$0.00 Strike: $63.22	$0.00	Disclosure SEC source: 0001127602-20-018755 · form4.xml · derivative · entry 20 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,834 Underlying: Common Stock · 10,000 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 02, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,812	$123.35	$346,854.86	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 11 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $123.065 to $123.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 02, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,909	$122.72	$356,978.81	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,952 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $122.06 to $123.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 02, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	1,353	$121.54	$164,440.51	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,861 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $121.05 to $122.015. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 02, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	765	$120.60	$92,262.29	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 8 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,214 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $119.95 to $120.935. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 02, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,161	$119.10	$257,379.21	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,979 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $118.70 to $119.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 02, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	10,000	$63.22	$632,200.00	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 01, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	10,000	$0.00 Strike: $63.22	$0.00	Disclosure SEC source: 0001127602-20-018755 · form4.xml · derivative · entry 19 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,834 Underlying: Common Stock · 10,000 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
June 01, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,490	$120.49	$300,019.10	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $120.195 to $120.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 01, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	3,553	$119.78	$425,591.84	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,630 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $119.19 to $120.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 01, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	2,153	$118.65	$255,451.30	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,183 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $118.18 to $119.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 01, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	1,804	$117.35	$211,700.12	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,336 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $117.14 to $118.105. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 01, 2020 Filed Jun 3, 2020 22:28 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionCommon Stock	10,000	$63.22	$632,200.00	Disclosure SEC source: 0001127602-20-018755 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
May 29, 2020 Filed Jun 1, 2020 12:07 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	Exercise / conversionStock Options · Derivative	10,000	$0.00 Strike: $63.22	$0.00	Disclosure SEC source: 0001127602-20-018181 · form4.xml · derivative · entry 14 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,834 Underlying: Common Stock · 10,000 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. Read SEC document
May 29, 2020 Filed Jun 1, 2020 12:07 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	1,420	$117.84	$167,330.67	Disclosure SEC source: 0001127602-20-018181 · form4.xml · nonDerivative · entry 10 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $117.30 to $118.135. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 29, 2020 Filed Jun 1, 2020 12:07 UTC	UNITED THERAPEUTICS Corp UTHR · Entity 664	SaleCommon Stock	1,556	$116.53	$181,323.17	Disclosure SEC source: 0001127602-20-018181 · form4.xml · nonDerivative · entry 9 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,560 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. Assuming relevant conditions are met, this tranche of options will be exercised in daily installments of 10,000 shares during May-July, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $116.09 to $116.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.